Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives

Dow Jones

2024/12/27

By Stephen Nakrosis

Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options.

The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday.

The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding.

In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma.

After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more than 58%.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 26, 2024 17:02 ET (22:02 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2494135808"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2494135808\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2494135808?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-27 06:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2494135808","market":"sh","top_or_hot":-1,"title":"Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. \n</p>\n<p>\n  The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday. \n</p>\n<p>\n  The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding. \n</p>\n<p>\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma. \n</p>\n<p>\n  After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more than 58%. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2024 17:02 ET (22:02 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nViracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-27 06:02</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. \n</p>\n<p>\n  The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday. \n</p>\n<p>\n  The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding. \n</p>\n<p>\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma. \n</p>\n<p>\n  After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more than 58%. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 26, 2024 17:02 ET (22:02 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2494135808","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2494135808","pubTimestamp":1735250520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options.The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday.The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding.In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma.After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Viracta Therapeutics结束Naval-1临床试验，正在探索战略替代方案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIRX":0.9,"LENZ":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. \n\n\n  The strategic options being considered include a merger, licensing agreement, or sale, among other options, Viracta said Thursday. \n\n\n  The company said it is voluntarily closing a Phase 2 trial of Naval-1, which was evaluating the drug as a treatment for certain lymphoma patients, in order to maximize its cash runway. The company said the decision to end the trial was not the result of any new safety finding. \n\n\n  In November, the company said it was cutting its workforce and reducing the size of the board to six from 10. The company at the time also said it was enhancing its focus on developing Nana-val in certain patients with T-cell Lymphoma. \n\n\n  After the bell, Viracta's shares had fallen 19%, to trade at 20 cents per share. The stock closed Thursday's regular session at 23 cents per share. Year to date, the stock has fallen more than 58%. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 26, 2024 17:02 ET (22:02 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}